La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Allurion Technologies a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Allurion Technologies..

Allurion Technologies (NYSE:ALUR) Azioni, Catena delle Opzioni

Allurion Technologies

Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Allurion Technologies Inc

Allurion Technologies, Inc. Warrants, each whole warrant exercisable to purchase 1.420455 shares of common stock at an exercise price of $8.10 per share of common stock

<p>Wells Fargo  analyst Michael Sison   maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $105 to $107.</p>


News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on DuPont de Nemours, Raises Price Target to $107

<p>Wells Fargo  analyst Joseph O'Dea   maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Overweight and raises the price target from $128 to $135.</p>


Wells Fargo Maintains Overweight on Emerson Electric, Raises Price Target to $135

<p>Movie theater company <strong>AMC Entertainment Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) could highlight market share gains and a strong box office performance when the company reports third-quarter financial results Wednesday<a href="https://www.benzinga.com/earnings"> after the market close.</a></p>
<p>AMC <strong>Earnings Estimates: </strong>Analysts expect AMC to report third-quarter revenue of $1.33 billion, down from $1.41 billion in last year's third quarter, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">from Benzinga Pro.</a></p>
<p>The company has beaten revenue estimates from analysts in nine of the last 10 quarters, missing in the most recently reported second quarter.</p>
<p>Analysts expect the company to report a loss of 11 cents per share, compared to a loss of 9 cents per share in last year's third quarter. The company has beaten analyst estimates for earnings per share in seven of the last eight quarters, meeting expectations in the most recently reported second quarter.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/general/entertainment/24/09/41073813/amc-survival-against-challenging-sector-brings-magic-comparison-harry-houdini-works-at-amc">AMC Survival Against Challenging Sector Brings Magic Comparison: &#8216;Harry Houdini Works At AMC&#8217;</a></strong></p>
<p><strong>What AMC</strong> <strong>Analysts Are Saying</strong>: Wedbush analyst Alicia Reese <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40165453/amc-stock-to-remain-volatile-after-q2-results-analysts-praise-market-share-gains-ca">detailed the company's</a> potential market share gains in an investor note after second-quarter financial results.</p>
<p>The analyst, who has a Neutral rating and a $4 price target, said the company needs to reduce its high debt load to help with future growth.</p>
<p>"AMC can also drive revenue growth in Europe with theater upgrades. However, it is unlikely to do so until it works through balance sheet right-sizing," Reese said.</p>
<p>The analyst said a large network of premium screens and concert movie distribution deals could help "justify its premium valuation," but cautioned on more potential capital needed to cover interest payments.</p>
<p>&#8220;We expect AMC&#8217;s shares to remain volatile as its shareholders dislike its frequent share issuances.&#8221;</p>
<p>Benchmark analyst Mike Hickey said AMC's second quarter saw a strong performance with several box office hits.</p>
<p>The analyst, who has a Market Weight rating and no price target, said the concession revenue per attendee was up in the second quarter for domestic theaters along with higher average ticket prices, positives for the company.</p>
<p><strong>Key Items to Watch From AMC: </strong>The third-quarter box office rose 0.6% year-over-year domestically according to <a href="https://www.boxofficemojo.com/quarter/q3/?grossesOption=calendarGrosses">data </a>from BoxOfficeMojo. The quarter saw hit films like "Deadpool &amp; Wolverine," "Despicable Me 4," "Twisters" and "Beetlejuice Beetlejuice" released.</p>
<p>AMC's quarterly report comes after peer <strong>Cinemark Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) <a href="https://www.benzinga.com/news/earnings/24/10/41660851/whats-going-on-with-cinemark-holdings-stock-thursday">reported quarterly earnings </a>that saw earnings per share and revenue both beat analyst estimates. The <span style="box-sizing: border-box; margin: 0px; padding: 0px;">company&#8217;s shar</span>es rose after the report, and analysts raised<a href="https://www.benzinga.com/quote/CNK/analyst-ratings"> their price targets.</a></p>
<p>Cinemark said the third quarter box office exceeded expectations and was the highest quarterly total since the COVID-19 pandemic.</p>
<p>A similar report from AMC could go a long way toward showing a box office recovery and growth ahead.</p>
<p>Fourth-quarter domestic box office hasn't been as strong, with "Venom: The Last Dance" the current top film of the quarter at $92.0 million. Upcoming movies like "Gladiator II," "Moana 2," "Wicked," "Sonic the Hedgehog 3" and "Mufasa: The Lion King" could bring optimism for a strong end to the year for movie theater companies.</p>
<p><span style="box-sizing: border-box; margin: 0px; padding: 0px;">AMC CEO <strong>Adam Aron </strong>has been more optimistic about upcoming years than 2024, which could be echoed in his commentary on Wednesday.</span></p>
<p>&#8220;With a long list of blockbuster movie titles opening in theaters during the remainder of the year and into 2025 and 2026, the industry-wide box office now appears to us to be poised for sustained growth. Looking ahead, we believe that bodes ever so well for the increasing cash generation potential from AMC&#8217;s movie theaters both at home and abroad," Aron said earlier this year.</p>
<p><strong>AMC Price Action:</strong> AMC stock was up 2.3% to $4.50 on Wednesday versus a 52-week trading range of $2.38 to $11.88. AMC stock is down 28% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/entertainment/24/05/39010959/amc-ceo-says-were-still-here-how-taylor-swift-popcorn-buckets-help-movie-theater-from-going">AMC CEO Says &#8216;We&#8217;re Still Here&#8217;: How Taylor Swift, Popcorn Buckets Help Movie Theater From Going &#8216;Kaplooey&#8217;</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Entertainment

Previews

Trading Ideas

AMC Q3 Earnings Preview: Can 'Deadpool & Wolverine' Box Office Strength Lift Stock?

<p>Wells Fargo  analyst Jason Haas   maintains UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) with a Overweight and raises the price target from $56 to $62.</p>


Wells Fargo Maintains Overweight on UL Solutions, Raises Price Target to $62

<p><a href="https://thebearcave.substack.com/p/problems-at-viasat-vsat" title="https://thebearcave.substack.com/p/problems-at-viasat-vsat">https://thebearcave.substack.com/p/problems-at-viasat-vsat</a></p>


VSAT

Watching Viasat; The Bear Cave Newsletter Issues Report Titled 'Problems at Viasat (VSAT)'

<p>Susquehanna  analyst Christopher Rolland   maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Neutral and lowers the price target from $260 to $250.</p>


NXPI

Susquehanna Maintains Neutral on NXP Semiconductors, Lowers Price Target to $250

<p>Wells Fargo  analyst Jason Haas   maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Underweight and raises the price target from $460 to $470.</p>


Wells Fargo Maintains Underweight on Gartner, Raises Price Target to $470

<p>Susquehanna  analyst Christopher Rolland   maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Positive and lowers the price target from $95 to $90.</p>


MCHP

Susquehanna Maintains Positive on Microchip Technology, Lowers Price Target to $90

<p>Financial giants have made a conspicuous bearish move on Freeport-McMoRan. Our analysis of options history for Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) revealed 16 unusual trades.</p>
<p>Delving into the details, we found 31% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $57,912, and 14 were calls, valued at $1,995,172.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $33.0 and $50.0 for Freeport-McMoRan, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Freeport-McMoRan's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Freeport-McMoRan's whale activity within a strike price range from $33.0 to $50.0 in the last 30 days. </p>
<h3>Freeport-McMoRan Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730907075_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.6</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$50.00</td>
<td>$520.3K</td>
<td>35.4K</td>
<td>5.1K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.43</td>
<td>$1.5</td>
<td>$50.00</td>
<td>$506.2K</td>
<td>35.4K</td>
<td>10.7K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$50.00</td>
<td>$204.1K</td>
<td>35.4K</td>
<td>5.1K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.49</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$50.00</td>
<td>$139.3K</td>
<td>35.4K</td>
<td>7.4K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.45</td>
<td>$1.43</td>
<td>$1.43</td>
<td>$50.00</td>
<td>$98.6K</td>
<td>35.4K</td>
<td>6.4K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Freeport-McMoRan</h3>
<p>Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.</p>
<p>After a thorough review of the options trading surrounding Freeport-McMoRan, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>With a volume of 3,545,458, the price of FCX is down -2.09% at $46.01. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Freeport-McMoRan</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $54.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Freeport-McMoRan with a target price of $57.<br />
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Freeport-McMoRan, which currently sits at a price target of $53.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Freeport-McMoRan, targeting a price of $55. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

This Is What Whales Are Betting On Freeport-McMoRan

<p>Financial giants have made a conspicuous bullish move on Mastercard. Our analysis of options history for Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 33% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $98,538, and 7 were calls, valued at $507,653.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $390.0 to $530.0 for Mastercard during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Mastercard stands at 232.62, with a total volume reaching 226.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Mastercard, situated within the strike price corridor from $390.0 to $530.0, throughout the last 30 days.</p>
<h3>Mastercard Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730907070_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$124.65</td>
<td>$121.65</td>
<td>$123.99</td>
<td>$400.00</td>
<td>$99.1K</td>
<td style="text-align: right;">487</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$133.4</td>
<td>$129.0</td>
<td>$129.0</td>
<td>$420.00</td>
<td>$90.4K</td>
<td style="text-align: right;">183</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$155.85</td>
<td>$153.5</td>
<td>$153.55</td>
<td>$390.00</td>
<td>$76.7K</td>
<td style="text-align: right;">33</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$150.35</td>
<td>$145.25</td>
<td>$145.25</td>
<td>$400.00</td>
<td>$72.6K</td>
<td style="text-align: right;">198</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$7.05</td>
<td>$6.9</td>
<td>$7.05</td>
<td>$520.00</td>
<td>$70.6K</td>
<td style="text-align: right;">801</td>
<td style="text-align: right;">98</td>
</tr>
</tbody>
</table>
</p>
<h3>About Mastercard</h3>
<p>Mastercard is the second-largest payment processor in the world, having processed close to over $9 trillion in volume during 2023. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.</p>
<h3>Current Position of Mastercard</h3>
<ul>
<li>With a volume of 778,613, the price of MA is up 2.7% at $519.19. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mastercard</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $565.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Macquarie keeps a Outperform rating on Mastercard with a target price of $565.<br />
&#x2A; An analyst from Keybanc persists with their Overweight rating on Mastercard, maintaining a target price of $580.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Mastercard, maintaining a target price of $544.<br />
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Mastercard, targeting a price of $605.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Mastercard, targeting a price of $532. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Mastercard with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Mastercard Options Trading: A Deep Dive into Market Sentiment

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Moderna</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Moderna.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $214,735, and 7 are calls, for a total amount of $478,040.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $130.0 for Moderna over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Moderna's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $40.0 to $130.0 in the last 30 days. </p>
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730907065_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.31</td>
<td>$1.27</td>
<td>$1.31</td>
<td>$60.00</td>
<td>$107.5K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.55</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$50.00</td>
<td>$105.8K</td>
<td>4.7K</td>
<td>513</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$16.7</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$88.2K</td>
<td>40</td>
<td>150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.0</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$78.2K</td>
<td>40</td>
<td>97</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.4</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$73.2K</td>
<td>40</td>
<td>50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Moderna</h3>
<p>Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.</p>
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,021,467, with MRNA's price down by -1.31%, positioned at $52.59.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $69.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Bernstein has revised its rating downward to Market Perform, adjusting the price target to $55.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Moderna, maintaining a target price of $108.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $59.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on Moderna with a target price of $55. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


MRNA

Moderna Options Trading: A Deep Dive into Market Sentiment

<p><a href="https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html" title="https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html">https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html</a></p>


PLNT

'Planet Fitness wants to acquire bankrupt budget-fitness chain Blink Holdings' - CNBC

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories 0.412M Barrel Build Vs 1.650M Barrel Draw Est.; 2.707M Barrel Draw Prior

EIA Weekly Distillates Stocks 2.947M Barrel Build Vs 1.500M Barrel Draw Est.; 0.977M Barrel Draw Prior

<p>Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) has outperformed the market over the past 5 years by 15.97% on an annualized basis producing an average annual return of 29.67%. Currently, Iron Mountain has a market capitalization of $37.08 billion. </p>
<p><strong>Buying $100 In IRM:</strong> If an investor had bought $100 of IRM stock 5 years ago, it would be worth <strong>$364.41</strong> today based on a price of $126.40 for IRM at the time of writing.</p>
<h3>Iron Mountain's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730907021_0_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In Iron Mountain 5 Years Ago Would Be Worth This Much Today

<p>Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 6.16% on an annualized basis producing an average annual return of 19.86%. Currently, Williams Companies has a market capitalization of $66.91 billion. </p>
<p><strong>Buying $1000 In WMB:</strong> If an investor had bought $1000 of WMB stock 5 years ago, it would be worth <strong>$2,469.20</strong> today based on a price of $53.05 for WMB at the time of writing.</p>
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730907016_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

<p>Wells Fargo  analyst Brandon Couillard   maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $78 to $75.</p>


BRKR

Wells Fargo Maintains Overweight on Bruker, Lowers Price Target to $75

Macro Notification

General

USA Crude Oil Inventories 2.149M Barrel Build Vs 0.300M Barrel Build Est.; 0.515M Barrel Draw Prior

<p>Susquehanna  analyst Mehdi Hosseini   maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $50 to $48.</p>


Susquehanna Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $48

<p>RBC Capital  analyst Jimmy Shan   maintains Colliers Intl Gr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CIGI#TSX">CIGI</a>) with a Outperform and lowers the price target from C$174 to C$170.</p>


CIGI

TSX:CIGI

RBC Capital Maintains Outperform on Colliers Intl Gr, Lowers Price Target to C$170

Allurion Technologies (ALUR) has provided an announcement. Allurion Technologies, Inc. has been notified by the New York Stock Exchange (NYSE) that...

Allurion Technologies Faces NYSE Delisting Risk and Considers Remedies

The latest update is out from Allurion Technologies (ALUR). Allurion Technologies, Inc. has expanded its Board of Directors, appointing Keith Johns...

Allurion Technologies Appoints New Class III Director

Allurion Technologies ( ($ALUR) ) has provided an announcement. Allurion Technologies, Inc., a healthcare company focused on obesity treatments, ha...

Allurion Technologies Faces NYSE Compliance Hurdle

Allurion receives non-compliance notice from NYSE

Allurion Technologies (ALUR) has received a new Buy rating, initiated by Roth MKM analyst, Jason Wittes. Jason Wittes has given his Buy rating due ...

Innovative Weight Loss Solution and Strong Market Potential: A 'Buy' Rating for Allurion Technologies

Allurion started at buy by Roth MKM over weight-loss device potential

Josh Jennings, an analyst from TD Cowen, has initiated a new Buy rating on Allurion Technologies (ALUR). Josh Jennings has given his Buy rating due...

Innovative Product and Robust Business Model Fuel Buy Rating for Allurion Technologies

Allurion started at buy by Jefferies ahead of data for obesity therapy

Allurion Technologies (ALUR) announced the presentation of two abstracts at Obesity Week, the annual meeting of The Obesity Society. The first abst...

Allurion Technologies presents data at Obesity Week

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Allurion Technologies (ALUR – Research Report), with a price tar...

Allurion Technologies' Platform Shows Promising Weight Loss Results, Boosting Confidence in Commercial Potential

ALUR

Press Releases

Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Coverage Initiation And Bullish Price Target Sends Micro Cap Flying

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Comments

Allurion Technologies

Allurion Technologies (ALUR) Opzioni

Allurion Technologies (NYSE:ALUR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO